Exploring the Potential of Large Language models in Traditional Korean Medicine: A Foundation Model Approach to Culturally-Adapted Healthcare

Introduction: Traditional Korean medicine (TKM) emphasizes individualized diagnosis and treatment, making AI modeling difficult due to limited data and implicit processes. GPT-3.5 and GPT-4, large language models, have shown impressive medical knowledge despite lacking medicine-specific training. This study aimed to assess the capabilities of GPT-3.5 and GPT-4 for TKM using the Korean National Licensing Examination for Korean Medicine Doctors. Methods: GPT-3.5 (February 2023) and GPT-4 (March 2023) models answered 340 questions from the 2022 examination across 12 subjects. Each question was independently evaluated five times in an initialized session. Results: GPT-3.5 and GPT-4 achieved 42.06% and 57.29% accuracy, respectively, with GPT-4 nearing passing performance. There were significant differences in accuracy by subjects, with 83.75% accuracy for neuropsychiatry compared to 28.75% for internal medicine (2). Both models showed high accuracy in recall-based and diagnosis-based questions but struggled with intervention-based ones. The accuracy for questions that require TKM-specialized knowledge was relatively lower than the accuracy for questions that do not GPT-4 showed high accuracy for table-based questions, and both models demonstrated consistent responses. A positive correlation between consistency and accuracy was observed. Conclusion: Models in this study showed near-passing performance in decision-making for TKM without domain-specific training. However, limits were also observed that were believed to be caused by culturally-biased learning. Our study suggests that foundation models have potential in culturally-adapted medicine, specifically TKM, for clinical assistance, medical education, and medical research.Comment: 31 pages, 6 figure

Investigating the Biomarkers of the Sasang Constitution via Network Pharmacology Approach

Sasang constitutional (SC) medicine classifies people into Soeum (SE), Soyang (SY), Taeeum (TE), and Taeyang (TY) types based on psychological and physical traits. However, biomarkers of these types are still unclear. We aimed to identify biomarkers among the SC types using network pharmacology methods. Target genes associated with the SC types were identified by grouping herb targets that preserve and strengthen the requisite energy (Bomyeongjiju). The herb targets were obtained by constructing an herb-compound-target network. We identified 371, 185, 146, and 89 target genes and their unique biological processes related to SE, SY, TE, and TY types, respectively. While the targets of SE and SY types were the most similar among the target pairs of the SC types, those of TY type overlapped with only a few other SC-type targets. Moreover, SE, SY, TE, and TY were related to “diseases of the digestive system,” “diseases of the nervous system,” “endocrine, nutritional, and metabolic diseases,” and “congenital malformations, deformations, and chromosomal abnormalities,” respectively. We successfully identified the target genes, biological processes, and diseases related to each SC type. We also demonstrated that a drug-centric approach using network pharmacology analysis provides a deeper understanding of the concept of Sasang constitutional medicine at a phenotypic level

A System-Level Mechanism of Anmyungambi Decoction for Obesity: A Network Pharmacological Approach

Obesity is a low-grade systemic inflammatory disease involving adipocytokines. As though Anmyungambi decoction (AMGB) showed significant improvement on obesity in a clinical trial, the molecular mechanism of AMGB in obesity remains unknown. Therefore, we explored the potential mechanisms of action of AMGB on obesity through network pharmacological approaches. We revealed that targets of AMGB are significantly associated with obesity-related and adipocyte-elevated genes. Evodiamine, berberine, genipin, palmitic acid, genistein, and quercetin were shown to regulate adipocytokine signaling pathway proteins which mainly involved tumor necrosis factor receptor 1, leptin receptor. In terms of the regulatory pathway of lipolysis in adipocytes, norephedrine, pseudoephedrine, quercetin, and limonin were shown to affect adrenergic receptor-beta, protein kinase A, etc. We also found that AMGB has the potentials to enhance the insulin signaling pathway thereby preventing type II diabetes mellitus. Additionally, AMGB was discovered to be able to control not only insulin-related proteins but also inflammatory mediators and apoptotic regulators and caspases, hence reducing hepatocyte injury in nonalcoholic fatty liver disease. Our findings help develop a better understanding of how AMGB controls obesity

Predicting activatory and inhibitory drug-target interactions based on structural compound representations and genetically perturbed transcriptomes.

A computational approach to identifying drug-target interactions (DTIs) is a credible strategy for accelerating drug development and understanding the mechanisms of action of small molecules. However, current methods to predict DTIs have mainly focused on identifying simple interactions, requiring further experiments to understand mechanism of drug. Here, we propose AI-DTI, a novel method that predicts activatory and inhibitory DTIs by combining the mol2vec and genetically perturbed transcriptomes. We trained the model on large-scale DTIs with MoA and found that our model outperformed a previous model that predicted activatory and inhibitory DTIs. Data augmentation of target feature vectors enabled the model to predict DTIs for a wide druggable targets. Our method achieved substantial performance in an independent dataset where the target was unseen in the training set and a high-throughput screening dataset where positive and negative samples were explicitly defined. Also, our method successfully rediscovered approximately half of the DTIs for drugs used in the treatment of COVID-19. These results indicate that AI-DTI is a practically useful tool for guiding drug discovery processes and generating plausible hypotheses that can reveal unknown mechanisms of drug action

Overview of the drug–target interaction dataset for model training and external validation.

Overview of the drug–target interaction dataset for model training and external validation.</p

Candidate FDA-approved drugs for COVID-19-related activatory targets.

Candidate FDA-approved drugs for COVID-19-related activatory targets.</p

Candidate FDA-approved drugs for COVID-19-related inhibitory targets.

Candidate FDA-approved drugs for COVID-19-related inhibitory targets.</p

Assessment of performance using the original datasets through fivefold cross-validation.

Assessment of performance using the original datasets through fivefold cross-validation.</p

A Systems-Level Analysis of Mechanisms of <i>Platycodon grandiflorum</i> Based on A Network Pharmacological Approach

Platycodon grandiflorum (PG) is widely used in Asia for its various beneficial effects. Although many studies were conducted to understand the molecular mechanisms of PG, it is still unclear how the combinations of multiple ingredients work together to exert its therapeutic effects. The aim of the present study was to provide a comprehensive review of the systems-level mechanisms of PG by adopting network pharmacological analysis. We constructed a compound&#8315;target&#8315;disease network for PG using experimentally validated and machine-leaning-based prediction results. Each target of the network was analyzed based on previously known pharmacological activities of PG. Gene ontology analysis revealed that the majority of targets were related to cellular and metabolic processes, responses to stimuli, and biological regulation. In pathway enrichment analyses of targets, the terms related to cancer showed the most significant enrichment and formed distinct clusters. Degree matrix analysis for target&#8315;disease associations of PG suggested the therapeutic potential of PG in various cancers including hepatocellular carcinoma, gastric cancer, prostate cancer, small-cell lung cancer, and renal cell carcinoma. We expect that network pharmacological approaches will provide an understanding of the systems-level mechanisms of medicinal herbs and further develop their therapeutic potentials